Usefulness of advanced-platelet rich fibrin (A-PRF) and injectable-platelet rich fibrin (i-PRF) in the management of a massive medication-related osteonecrosis of the jaw (MRONJ): A 5-years follow-up case report

Giudice, Amerigo; Antonelli, Alessandro; Muraca, Danila; Lombardo, Fortunato

doi:10.4103/ijdr.ijdr_689_19

Cited by 31 publications

(12 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Particularly, the prevalence of medication adherence has been reported to range from 12.9 to 95.4%, and it has been highlighted that even up to 30% of patients do not start oral BP treatment after prescription [56][57][58][59][60][61][62]. Misconceptions about the risk of the rare BP-related adverse events such as osteonecrosis of the jaw, which remains a rare event in patients treated for osteoporosis, may even facilitate a treatment gap [63][64][65][66]. Hiligsmann et al showed that the one year BP persistence rate ranges from 16 to 60%, suggesting 40% of patients discontinue treatment within the first 12 months [18].…”

Section: Discussionmentioning

confidence: 99%

Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up

Martino

Bellone

Vicario

et al. 2021

IJERPH

View full text Add to dashboard Cite

Clinical psychological factors may predict medical diseases. Anxiety level has been associated with osteoporosis, but its role on bone mineral density (BMD) change is still unknown. This study aimed to investigate the association between anxiety levels and both adherence and treatment response to oral bisphosphonates (BPs) in postmenopausal osteoporosis. BMD and anxiety levels were evaluated trough dual-energy X-ray absorptiometry and the Hamilton Anxiety Rating Scale (HAM-A), respectively. Participants received weekly medication with alendronate or risedronate and were grouped according to the HAM-A scores into tertiles (HAM-A 3 > HAM-A 2 > HAM-A 1). After 24 months, BMD changes were different among the HAM-A tertiles. The median lumbar BMD change was significantly greater in both the HAM-A 2 and HAM-A 3 in comparison with the HAM-A 1. The same trend was observed for femoral BMD change. Adherence to BPs was >75% in 68% of patients in the HAM-A 1, 79% of patients in the HAM-A 2, and 89% of patients in the HAM-A 3 (p = 0.0014). After correcting for age, body mass index, depressive symptoms, and the 10-yr. probability of osteoporotic fractures, anxiety levels independently predicted lumbar BMD change (β = 0.3417, SE 0.145, p = 0.02). In conclusion, women with higher anxiety levels reported greater BMD improvement, highlighting that anxiety was associated with adherence and response to osteoporosis medical treatment, although further research on this topic is needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up

Martino

Bellone

Vicario

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Jensen and Lund [ 25 ] revealed that more severe OI patients were associated with more severe craniofacial abnormalities. Furthermore, since bisphosphonate (BP) treatment remains the first line medical management, particular attention should be paid to the risk of developing osteonecrosis of the jaw (ONJ) and the management of this possible complication [ 26 , 27 , 28 ]. However, the literature confirmed the lack of BP-related ONJ occurrence in the pediatric population suffering OI and treated with BP [ 29 ].…”

Section: Introductionmentioning

confidence: 99%

Dentinogenesis Imperfecta and Caries in Osteogenesis Imperfecta among Vietnamese Children

Nguyen

et al. 2021

Dentistry Journal

View full text Add to dashboard Cite

Osteogenesis imperfecta (OI) is a genetic disorder characterized by increased bone fragility and low bone mass, caused mainly by mutations in collagen type I encoding genes. The current study aimed to evaluate dentinogenesis imperfecta (DI), oral manifestations and caries status of OI children. Sixty-eight children (41 males, 27 females) aged from 3 to 17 years old (mean 9 ± 4.13) participated in the study. Participants were classified into three OI type groups (I—2 cases, III—31 cases and IV—35 cases). Clinical examination and an orthopantomogram were used to obtain prevalences and associations of DI, caries status, malocclusion, crossbite, open bite, eruption, impaction and missing teeth with OI. The prevalence of DI among OI patients was 47.1%, more common in OI type III than type IV. The yellow-brown discoloration type was more vulnerable to attrition than the opalescent-grey one in the primary dentition. OI seemed not to have a high risk of caries; the prevalence of caries was 69.1%. A high incidence of malocclusion, crossbite and open bite was observed. In-depth oral information would provide valuable data for better dental management in OI patients. Parents and general doctors should pay more attention to dental care to prevent caries and premature tooth loss.

show abstract

“…Moreover, the effect of bisphosphonates on the osteogenic activity of osteoprogenitor cells cultured on titanium surfaces has been investigated [ 13 ]. Further, innovative therapeutic approaches have been evaluated including fluorescence-guided bone surgery [ 14 ], ozone [ 15 ], advanced-platelet rich fibrin (A-PRF) and injectable-platelet rich fibrin (i-PRF) [ 16 ], and laser combined with platelet-rich plasma [ 17 ]. Discoveries on oral mesenchymal stem cell-derived exosomes have been reported in a recent review [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know

Bruckmoser

Palaoro

Latzko

et al. 2021

IJERPH

View full text Add to dashboard Cite

Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of antiresorptive drugs. In this online survey, the awareness and knowledge of dentists regarding MRONJ was evaluated, and potential implications for oncologists are discussed. Questionnaires were emailed to dentists from Germany, Austria, Switzerland, and South Tyrol to evaluate disease-related knowledge and management. In addition to the overall score, a separate score was calculated for knowledge (maximum score: 15 points) and management (maximum score: 6 points) questions, and 1197 valid replies with completed questionnaires were received. The mean overall score was 10.45 ± 3.97 points, the mean knowledge score was 7.68 ± 3.05 points, and the mean management score was 2.76 ± 1.77 points. Factors influencing the outcome of the overall score were age, specialization, continuous professional education, and the number of dental screening exams in patients before antiresorptive therapy. Due to the considerable lack of knowledge regarding MRONJ among dentists, MRONJ patients and subjects at risk should be guided towards specialists for dental screening, treatment, and follow-up. This is important from an oncologic point of view to avoid any delay for treatment start of antiresorptives, and to reveal a potentially emerging osteonecrosis at an early stage, thus, avoiding the need for interruption or even cancellation of antiresorptive therapy.

show abstract

Usefulness of advanced-platelet rich fibrin (A-PRF) and injectable-platelet rich fibrin (i-PRF) in the management of a massive medication-related osteonecrosis of the jaw (MRONJ): A 5-years follow-up case report

Cited by 31 publications

References 2 publications

Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up

Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up

Dentinogenesis Imperfecta and Caries in Osteogenesis Imperfecta among Vietnamese Children

Choosing the Right Partner for Medication Related Osteonecrosis of the Jaw: What Central European Dentists Know

Contact Info

Product

Resources

About